766 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
ABBV AbbVie Inc. $95.37 $144.42B N/A
Article Searches
What's in the Cards for AbbVie (ABBV) This Earnings Season? http://www.zacks.com/stock/news/584231/whats-in-the-cards-for-abbvie-abbv-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-584231 Oct 25, 2019 - AbbVie's (ABBV) Q3 sales may have been weighed down by biosimilar competition for Humira in international markets. However, strong growth of oncology drugs might have offset impact of Humira's international sales erosion.
AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth http://www.zacks.com/stock/news/584118/abbvie-abbv-reports-next-week-wall-street-expects-earnings-growth?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-584118 Oct 25, 2019 - AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen (BIIB) Beats on Q3 Earnings, Eyes FDA Nod for Aducanumab http://www.zacks.com/stock/news/577137/biogen-biib-beats-on-q3-earnings-eyes-fda-nod-for-aducanumab?cid=CS-ZC-FT-analyst_blog|earnings_article-577137 Oct 22, 2019 - Biogen (BIIB) beats estimates for both earnings and sales in the third quarter. It is set to pursue FDA approval of aducanumab. Shares skyrocket in pre-market trading.
What's in Store for Healthcare ETFs in Q3 Earnings? http://www.zacks.com/stock/news/575582/whats-in-store-for-healthcare-etfs-in-q3-earnings?cid=CS-ZC-FT-etf_news_and_commentary-575582 Oct 21, 2019 - With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.
3 Stocks With Fast-Growing Dividends That Retirees Will Love https://www.fool.com/investing/2019/10/20/3-stocks-with-fast-growing-dividends-that-retirees.aspx?source=iedfolrf0000001 Oct 20, 2019 - These solid companies have boosted their dividends by at least 67% over the last three years.
Novartis' Jakavi Meets Primary Goal in Phase III for GVHD http://www.zacks.com/stock/news/569743/novartis-jakavi-meets-primary-goal-in-phase-iii-for-gvhd?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-569743 Oct 17, 2019 - Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.
Top Ranked Income Stocks to Buy for October 17th http://www.zacks.com/commentary/569086/top-ranked-income-stocks-to-buy-for-october-17th?cid=CS-ZC-FT-zacks_#1_rank_additions-569086 Oct 17, 2019 - Top Ranked Income Stocks to Buy for October 17th
Reata Pharmaceuticals Repositions Itself for Success https://www.fool.com/investing/2019/10/16/reata-pharmaceuticals-repositions-itself-for-succe.aspx?source=iedfolrf0000001 Oct 16, 2019 - The company reclaimed rights to several promising drug candidates last week; this week, positive data from a pivotal clinical trial sent it soaring.
Here is Why Growth Investors Should Buy AbbVie (ABBV) Now http://www.zacks.com/stock/news/567217/here-is-why-growth-investors-should-buy-abbvie-abbv-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_11_growth-567217 Oct 16, 2019 - AbbVie (ABBV) possesses solid growth attributes, which could help it handily outperform the market.
Top Ranked Momentum Stocks to Buy for October 16th http://www.zacks.com/commentary/567183/top-ranked-momentum-stocks-to-buy-for-october-16th?cid=CS-ZC-FT-zacks_#1_rank_additions-567183 Oct 16, 2019 - Top Ranked Momentum Stocks to Buy for October 16th

Pages: 12345678...77

<<<Page 3>